Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Novo Nordisk's next gen obesity drug CagriSema trial results disappoint investors CagriSema vs. Semaglutide: Which is Better for Weight Loss? CagriSema SEMAGLUTIDE IN ADULTS WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES MELLITUS.pptx New Weight Loss Drug CagriSema Shows Impressive Results in Clinical Trials Cagrilintide is a novel, long acting peptide designed to target multiple receptors involved in appetite regulation and energy balance. Unlike traditional weight loss medications that often target a single pathway, cagrilintide acts as